98 related articles for article (PubMed ID: 26212264)
1. HDL as a Target for Glycemic Control.
Waldman B; Jenkins AJ; Sullivan D; Ng MKC; Keech AC
Curr Drug Targets; 2017; 18(6):651-673. PubMed ID: 26212264
[TBL] [Abstract][Full Text] [Related]
2. Modulation of the pancreatic islet-stress axis as a novel potential therapeutic target in diabetes mellitus.
Ludwig B; Barthel A; Reichel A; Block NL; Ludwig S; Schally AV; Bornstein SR
Vitam Horm; 2014; 95():195-222. PubMed ID: 24559919
[TBL] [Abstract][Full Text] [Related]
3. HDLs, diabetes, and metabolic syndrome.
Vollenweider P; von Eckardstein A; Widmann C
Handb Exp Pharmacol; 2015; 224():405-21. PubMed ID: 25522996
[TBL] [Abstract][Full Text] [Related]
4. Triglycerides to high-density lipoprotein-cholesterol ratio, glycemic control and cardiovascular risk in obese patients with type 2 diabetes.
Quispe R; Martin SS; Jones SR
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):150-6. PubMed ID: 26863278
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of apolipoprotein E secretion by macrophages in type 2 diabetic patients: role of HDL and apolipoprotein A-I.
Yamato K; Tamasawa N; Murakami H; Matsui J; Tanabe J; Suda T; Yasujima M
Diabetes Res Clin Pract; 2005 Aug; 69(2):124-8. PubMed ID: 16005361
[TBL] [Abstract][Full Text] [Related]
6. Effects of high-density lipoproteins on pancreatic beta-cell insulin secretion.
Fryirs MA; Barter PJ; Appavoo M; Tuch BE; Tabet F; Heather AK; Rye KA
Arterioscler Thromb Vasc Biol; 2010 Aug; 30(8):1642-8. PubMed ID: 20466975
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein E kinetics: influence of insulin resistance and type 2 diabetes.
Bach-Ngohou K; Ouguerram K; Nazih H; Maugère P; Ripolles-Piquer B; Zaïr Y; Frénais R; Krempf M; Bard JM
Int J Obes Relat Metab Disord; 2002 Nov; 26(11):1451-8. PubMed ID: 12439646
[TBL] [Abstract][Full Text] [Related]
8. Thoughts on the progression of type 2 diabetes drug discovery.
Bhatt HB
Expert Opin Drug Discov; 2015 Feb; 10(2):107-10. PubMed ID: 25534140
[TBL] [Abstract][Full Text] [Related]
9. HDL-C and HDL-C/ApoA-I predict long-term progression of glycemia in established type 2 diabetes.
Waldman B; Jenkins AJ; Davis TM; Taskinen MR; Scott R; O'Connell RL; Gebski VJ; Ng MK; Keech AC;
Diabetes Care; 2014 Aug; 37(8):2351-8. PubMed ID: 24804699
[TBL] [Abstract][Full Text] [Related]
10. Apolipoprotein A-I interactions with insulin secretion and production.
Rye KA; Barter PJ; Cochran BJ
Curr Opin Lipidol; 2016 Feb; 27(1):8-13. PubMed ID: 26655291
[TBL] [Abstract][Full Text] [Related]
11. Altered HDL metabolism in metabolic disorders: insights into the therapeutic potential of HDL.
Hui N; Barter PJ; Ong KL; Rye KA
Clin Sci (Lond); 2019 Nov; 133(21):2221-2235. PubMed ID: 31722013
[TBL] [Abstract][Full Text] [Related]
12. Role of lipases, lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in abnormal high density lipoprotein metabolism in insulin resistance and type 2 diabetes mellitus.
de Vries R; Borggreve SE; Dullaart RP
Clin Lab; 2003; 49(11-12):601-13. PubMed ID: 14651331
[TBL] [Abstract][Full Text] [Related]
13. Diabetes and branched-chain amino acids: What is the link?
Bloomgarden Z
J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
[TBL] [Abstract][Full Text] [Related]
14. Protection of pancreatic beta-cells: is it feasible?
Bonora E
Nutr Metab Cardiovasc Dis; 2008 Jan; 18(1):74-83. PubMed ID: 18096375
[TBL] [Abstract][Full Text] [Related]
15. Type II diabetes mellitus.
Edelman SV
Adv Intern Med; 1998; 43():449-500. PubMed ID: 9506190
[TBL] [Abstract][Full Text] [Related]
16. Pharmacologic treatment of type 2 diabetic dyslipidemia.
Moon YS; Kashyap ML
Pharmacotherapy; 2004 Dec; 24(12):1692-713. PubMed ID: 15585439
[TBL] [Abstract][Full Text] [Related]
17. Managing type 2 diabetes: going beyond glycemic control.
Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
[TBL] [Abstract][Full Text] [Related]
18. Low- and high-density lipoproteins modulate function, apoptosis, and proliferation of primary human and murine pancreatic beta-cells.
Rütti S; Ehses JA; Sibler RA; Prazak R; Rohrer L; Georgopoulos S; Meier DT; Niclauss N; Berney T; Donath MY; von Eckardstein A
Endocrinology; 2009 Oct; 150(10):4521-30. PubMed ID: 19628574
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological interventions that directly stimulate or modulate insulin secretion from pancreatic beta-cell: implications for the treatment of type 2 diabetes.
Farret A; Lugo-Garcia L; Galtier F; Gross R; Petit P
Fundam Clin Pharmacol; 2005 Dec; 19(6):647-56. PubMed ID: 16313276
[TBL] [Abstract][Full Text] [Related]
20. High-density lipoprotein in diabetes: Structural and functional relevance.
Lui DTW; Tan KCB
J Diabetes Investig; 2024 Jul; 15(7):805-816. PubMed ID: 38416054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
